Application segmentation delineates the end‑use categories that drive demand for contract manufacturing capacity. Therapeutic proteins—including monoclonal antibodies, fusion proteins, and cytokines—represent the largest share, accounting for roughly 55 % of total revenue, reflecting their dominance in oncology and autoimmune therapies. Vaccines contribute about 20 % of the market, supported by sustained public‑health programs and accelerated mRNA platform adoption. Cell‑based therapies, encompassing CAR‑T and allogeneic cell products, hold an estimated 15 % share, a figure that is expanding as regulatory pathways mature and payer acceptance improves. Diagnostic biologics, such as recombinant enzymes and biomarkers, occupy the remaining 10 % and are tied to growth in personalized medicine and point‑of‑care testing. Together, these application segments structure the overall Biologics Contract Manufacturing market, with each proportion directly influencing capacity planning, technology investment, and pricing dynamics. The distribution is visualized in the accompanying pie‑chart, reinforcing the relevance of Biologics Contract Manufacturing segmentation for strategic forecasting. These proportions also guide upstream supplier contracts and downstream quality assurance frameworks, ensuring alignment with therapeutic timelines.